- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02404792
Exercise for Healthy Aging: The Impact of HIV and Aging on Physical Function and the Somatopause
January 15, 2019 updated by: University of Colorado, Denver
The primary objective of this proposal is to compare a moderate or high intensity exercise intervention to improve physical function in persons aging with Human Immunodeficiency Virus (HIV).
Study Overview
Status
Completed
Conditions
Detailed Description
The primary objective of this proposal is to compare a moderate or high intensity exercise intervention to improve physical function in persons aging with HIV.
Both HIV-infected and HIV-uninfected older adults will be assigned to a moderate intensity cardiovascular and resistance training intervention for 12 weeks, and then randomized to either continue moderate intensity exercise, or increase to high intensity exercise for an additional 12 weeks.
The primary outcome is the impact of exercise on physical function, as measured by the overall score of a modified Short Physical Performance Battery (mSPPB) and the chair rise time from the mSPPB.
The secondary outcomes include changes in insulin-like growth factor-1 (systemic and local) and inflammation (interleukin-6 (IL-6), soluble tumor necrosis factor receptors 1 and 2 (sTNFR-1 and sTNFR-2)).
Study Type
Interventional
Enrollment (Actual)
69
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado- Anschutz Medical Campus
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ages 50-75
- HIV+ must be on ART for a minimum of 2 years with viral load <200 copies/mL
- Sedentary
- cluster of differentiation 4 (CD4) T-cell count >200 cells/microliter
- BMI >19 and <41
- Among females, must be post-menopausal
- Able to perform activities of daily living with out assistance
Exclusion Criteria:
- Diabetes, poorly controlled with HgbA1c >7.5; on insulin
- On growth hormone (or growth hormone axis) therapy, intramuscular testosterone, corticosteroids.
- Known active hepatitis B or C (viremia).
- Severe liver disease
- Uncontrolled hypertension (SPB >180 or diastolic >100).
- Underlying cardiac conditions that would make exercise or exercise testing potentially unsafe (unstable ischemic heart disease, Class III or IV heart failure clinically significant aortic stenosis, uncontrolled angina, or uncontrolled arrhythmia)
- pulmonary disease requiring the use of supplemental oxygen ≥ 4 liters with physical exertion
- current diagnosis of malignancy (excluding non-melanoma skin cancers) within 48 weeks prior to enrollment
- surgery/trauma/injury/fracture within 24 weeks prior to enrollment that may impact a subject's ability to exercise
- history of stroke with residual deficits that may impact ability to exercise; orthopedic problems (e.g., severe osteoarthritis, rheumatoid arthritis) that greatly limit the ability to perform moderate-intensity resistance exercise (e.g., unable to be properly positioned in exercise equipment or to have severely restricted range of motion even after modifications have been made)
- weight over 300 pounds
- Montreal Cognitive Assessment (MOCA) score < 18 (will be evaluated at screening visit after consent obtained)
- AIDS-defining opportunistic infection within the 24 weeks prior to enrollment
- Person who appear to have unstable health, are incapable of safely participating in the exercise intervention, or are felt to have a life expectancy of < 1 year.
- Participants on anticoagulants (clopidogrel, Coumadin, etc) will be excluded from the muscle biopsy.
- Aspirin and Non-steroidal anti-inflammatory agents are not exclusions but should be stopped 1 week prior to muscle biopsy (subset of subjects).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: HIV-uninfected
HIV-uninfected men and women, age 50-70 years.
All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.
|
|
Experimental: HIV-infected
HIV-infected men and women, age 50-70 years.
All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Rise From a Chair 10 Times (Modified From the Original Short Physical Performance Battery)
Time Frame: 24 weeks
|
Chair rise time is measured as a continuous variable of time to stand up from a sitting position 10 times.
Lower number = faster; larger number = slower
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Insulin-like Growth Factor (IGF)-1
Time Frame: 24 weeks
|
Measures at baseline and following 24 weeks of exercise
|
24 weeks
|
Changes in Inflammation (Interleukin-6 [IL-6], Soluble Tumor Necrosis Factor Receptors 1 and TNF-alpha.
Time Frame: Baseline and 24 weeks
|
The primary outcome is change from 0 to 24 weeks.
These changes in inflammation are measured at baseline (pre-exercise) and at 24 weeks (post exercise).
|
Baseline and 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kristine Erlandson, MD, MSc, University of Colorado, Denver
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Bowman ER, Wilson M, Riedl KM, MaWhinney S, Jankowski CM, Funderburg NT, Erlandson KM. Lipidome Alterations with Exercise Among People With and Without HIV: An Exploratory Study. AIDS Res Hum Retroviruses. 2022 Jul;38(7):544-551. doi: 10.1089/AID.2021.0154. Epub 2022 Apr 21.
- Erlandson KM, Liu J, Johnson R, Dillon S, Jankowski CM, Kroehl M, Robertson CE, Frank DN, Tuncil Y, Higgins J, Hamaker B, Wilson CC. An exercise intervention alters stool microbiota and metabolites among older, sedentary adults. Ther Adv Infect Dis. 2021 Jun 25;8:20499361211027067. doi: 10.1177/20499361211027067. eCollection 2021 Jan-Dec.
- Jankowski CM, Wilson MP, MaWhinney S, Reusch J, Knaub L, Hull S, Erlandson KM. Blunted Muscle Mitochondrial Responses to Exercise Training in Older Adults With HIV. J Infect Dis. 2021 Aug 16;224(4):679-683. doi: 10.1093/infdis/jiaa799.
- Erlandson KM, Wilson MP, MaWhinney S, Rapaport E, Liu J, Wilson CC, Rahkola JT, Janoff EN, Brown TT, Campbell TB, Jankowski CM. The Impact of Moderate or High-Intensity Combined Exercise on Systemic Inflammation Among Older Persons With and Without HIV. J Infect Dis. 2021 Apr 8;223(7):1161-1170. doi: 10.1093/infdis/jiaa494.
- Johs NA, Kellar-Guenther Y, Jankowski CM, Neff H, Erlandson KM. A qualitative focus group study of perceived barriers and benefits to exercise by self-described exercise status among older adults living with HIV. BMJ Open. 2019 Mar 7;9(3):e026294. doi: 10.1136/bmjopen-2018-026294.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2015
Primary Completion (Actual)
October 2, 2017
Study Completion (Actual)
March 1, 2018
Study Registration Dates
First Submitted
March 18, 2015
First Submitted That Met QC Criteria
March 31, 2015
First Posted (Estimate)
April 1, 2015
Study Record Updates
Last Update Posted (Actual)
January 16, 2019
Last Update Submitted That Met QC Criteria
January 15, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-2207
- K23AG050260 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
University of EdinburghUmeå UniversityCompletedSystemic Inflammation | Respiratory InflammationSweden
-
University of AarhusAarhus University Hospital; University of CopenhagenCompletedSystemic Inflammation | Airway InflammationDenmark
-
Sykehuset TelemarkRikshospitalet University Hospital; Helse Sor-OstCompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust ExposureNorway
-
Assistance Publique - Hôpitaux de ParisCompletedDigestive InflammationFrance
-
Pamukkale UniversityCompletedPeriodontal InflammationTurkey
-
Universidade Federal do ParaCompleted
-
KLE Society's Institute of Dental SciencesCompletedRegenerative InflammationIndia
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
Singapore National Eye CentreCompletedIntraocular Inflammation in ChildrenSingapore
Clinical Trials on High-intensity cardiovascular and resistance exercise
-
Universidade Federal do vale do São FranciscoCompletedPost-Exercise Hypotension
-
Riphah International UniversityCompletedPolycystic Ovary SyndromePakistan
-
Federal University of BahiaUnknown
-
Universidad Santo TomasUniversidad Nacional de Colombia; Universidad del RosarioCompletedObesity | Cognitive Function | Motor ActivityColombia
-
Kent State UniversityUnknownEndothelial Dysfunction | Autonomic DysfunctionUnited States
-
Mayo ClinicCompleted
-
Riphah International UniversityCompleted
-
University of South FloridaBrooke Army Medical CenterCompleted
-
University of NottinghamActive, not recruitingColorectal Cancer | Prostate CancerUnited Kingdom
-
University of Roma La SapienzaUniversity of Padova; University of Rome Foro ItalicoRecruitingType 1 Diabetes | ExerciseItaly